This review maps how neuropeptides in the trigeminal system either promote or suppress orofacial pain — with CGRP, substance P, and others driving pain, while opioid peptides, galanin, and oxytocin provide relief — identifying targets for new treatments.
10+ neuropeptides mappedin the trigeminal system — divided into pro-pain (CGRP, substance P, NPY, NKA, HK-1, VIP) and analgesic (opioids, galanin, oxytocin, orexin-A) roles for orofacial pain
What the researchers found
Neuropeptides in the trigeminal system play distinct roles: CGRP, substance P, NPY, NKA, HK-1, and VIP are pro-inflammatory and pro-nociceptive, while opioid peptides, galanin, oxytocin, and orexin-A are analgesic — identifying multiple therapeutic targets for orofacial pain.
Why it matters
Orofacial pain conditions (TMJ disorders, trigeminal neuralgia, dental pain) affect millions and are often poorly managed by existing treatments. Understanding which neuropeptides drive versus inhibit this pain opens doors to targeted therapies — notably, CGRP-blocking drugs have already revolutionized migraine treatment and may extend to orofacial pain.
The numbers in context
Multiple neuropeptides reviewed including CGRP, substance P, and others involved in trigeminal pain signaling.
How the study worked
Systematic literature review summarizing current research on neuropeptide functions and mechanisms in orofacial pain, covering CGRP, substance P, opioid peptides, galanin, and other neuropeptides in the trigeminal sensory system.
Who was studied
Review of neuropeptide roles in orofacial pain
What this study cannot tell us
Review article — synthesizes existing research rather than presenting new data. Many neuropeptide-targeting drugs for orofacial pain remain in preclinical stages. The interplay between multiple neuropeptides in vivo is more complex than studying individual peptides suggests. Clinical translation from trigeminal system research to effective therapies has historically been challenging.
How to read the evidence
Moderate — comprehensive review synthesizing substantial preclinical and some clinical evidence, but many proposed therapeutic targets remain unvalidated in clinical trials for orofacial pain specifically.
When this study was published
Published in 2024, providing an up-to-date summary of neuropeptide research in orofacial pain.
The bigger picture
The success of anti-CGRP antibodies for migraine demonstrates that neuropeptide-targeted therapy works. This review extends that framework to the broader orofacial pain landscape, suggesting that drugs targeting substance P, galanin agonists, or oxytocin could become next-generation treatments for facial pain conditions — potentially offering alternatives to opioid painkillers for millions of patients.
Questions still open
- Can anti-CGRP antibodies (already approved for migraine) be repurposed for other orofacial pain conditions like TMJ disorders?
- Could combination therapy targeting both pro-pain and pain-relieving neuropeptide pathways provide superior pain control?
- How do individual genetic variations in neuropeptide systems explain why some patients respond to treatments while others don't?
Common questions
What are neuropeptides and how do they control pain?
Could this research lead to new treatments for TMJ or dental pain?
Read the original research
Role of neuropeptides in orofacial pain: A literature review.
Journal of oral rehabilitation, 51(5), 898-908
Citation
Wang, Jian; Liu, Xiangtao; Gou, Junzhuo; Deng, Jing; Li, Mujia; Zhu, Yafen; Wu, Zhifang. (2024). Role of neuropeptides in orofacial pain: A literature review.. Journal of oral rehabilitation, 51(5), 898-908. https://doi.org/10.1111/joor.13656